These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 32859128)

  • 1. Microencapsulation of Fluticasone Propionate and Salmeterol Xinafoate in Modified Chitosan Microparticles for Release Optimization.
    Ainali NM; Xanthopoulou E; Michailidou G; Zamboulis A; Bikiaris DN
    Molecules; 2020 Aug; 25(17):. PubMed ID: 32859128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Systematic review and Meta-analysis on efficacy and safety of Liujunzi Decoction combined with Western medicine for stable chronic obstructive pulmonary disease].
    Yi-Ling F; Qing M; Xing L; Chang-Zheng F; Mao-Rong F; Qing C; Ning W; Qiu-Xiao MA; Ya-Ni H
    Zhongguo Zhong Yao Za Zhi; 2020 Nov; 45(22):5331-5343. PubMed ID: 33350192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
    Kim KS; Kim JH; Jin SG; Kim DW; Kim JO; Yong CS; Youn YS; Oh KT; Woo JS; Choi HG
    Pharm Dev Technol; 2018 Feb; 23(2):158-166. PubMed ID: 28612675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of salmeterol and magnesium isoglycyrrhizinate combination treatment in rats with chronic obstructive pulmonary disease.
    Yang Y; Huang L; Tian C; Qian B
    Sci Rep; 2022 Jul; 12(1):12334. PubMed ID: 35853985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of Poly(vinyl alcohol) on Nanoencapsulation of Budesonide in Chitosan Nanoparticles via Ionic Gelation and Its Improved Bioavailability.
    Michailidou G; Ainali NM; Xanthopoulou E; Nanaki S; Kostoglou M; Koukaras EN; Bikiaris DN
    Polymers (Basel); 2020 May; 12(5):. PubMed ID: 32408557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhaled salmeterol/fluticasone propionate combination in chronic obstructive pulmonary disease.
    Lyseng-Williamson KA; Keating GM
    Am J Respir Med; 2002; 1(4):273-82; discussion 283-4. PubMed ID: 14720047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
    Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD.
    Donohue JF; Kalberg C; Emmett A; Merchant K; Knobil K
    Treat Respir Med; 2004; 3(3):173-81. PubMed ID: 15219176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Formulation of a novel fixed dose combination of salmeterol xinafoate and mometasone furoate for inhaled drug delivery.
    Liu S; Watts AB; Du J; Bui A; Hengsawas S; Peters JI; Williams RO
    Eur J Pharm Biopharm; 2015 Oct; 96():132-42. PubMed ID: 26220015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients.
    Daley-Yates PT; Mehta R; Chan RH; Despa SX; Louey MD
    J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):279-89. PubMed ID: 24074143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Salmeterol and Fluticasone Propionate Delivered in Combination via Easyhaler and Diskus Dry Powder Inhalers in Healthy Subjects.
    Kirjavainen M; Mattila L; Vahteristo M; Korhonen J; Lähelmä S
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):290-297. PubMed ID: 29493402
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Super-hydrophilic and high strength polymeric foam dressings of modified chitosan blends for topical wound delivery of chloramphenicol.
    Michailidou G; Christodoulou E; Nanaki S; Barmpalexis P; Karavas E; Vergkizi-Nikolakaki S; Bikiaris DN
    Carbohydr Polym; 2019 Mar; 208():1-13. PubMed ID: 30658779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice.
    Soriano JB; Vestbo J; Pride NB; Kiri V; Maden C; Maier WC
    Eur Respir J; 2002 Oct; 20(4):819-25. PubMed ID: 12412670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Bronchodilator efficacy of combined salmeterol and tiotropium in patients with chronic obstructive pulmonary disease].
    Baloira Villar A; Vilariño Pombo C
    Arch Bronconeumol; 2005 Mar; 41(3):130-4. PubMed ID: 15766465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of an economic model to assess the cost effectiveness of treatment interventions for chronic obstructive pulmonary disease.
    Spencer M; Briggs AH; Grossman RF; Rance L
    Pharmacoeconomics; 2005; 23(6):619-37. PubMed ID: 15960557
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterisation of the aggregation behaviour in a salmeterol and fluticasone propionate inhalation aerosol system.
    Michael Y; Snowden MJ; Chowdhry BZ; Ashurst IC; Davies-Cutting CJ; Riley T
    Int J Pharm; 2001 Jun; 221(1-2):165-74. PubMed ID: 11397578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of particle deposition density of dry powders on the results produced by an in vitro test system simulating dissolution- and absorption rates in the lungs.
    Malmlöf M; Nowenwik M; Meelich K; Rådberg I; Selg E; Burns J; Mascher H; Gerde P
    Eur J Pharm Biopharm; 2019 Jun; 139():213-223. PubMed ID: 30862480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
    Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
    Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial.
    Aaron SD; Vandemheen KL; Fergusson D; Maltais F; Bourbeau J; Goldstein R; Balter M; O'Donnell D; McIvor A; Sharma S; Bishop G; Anthony J; Cowie R; Field S; Hirsch A; Hernandez P; Rivington R; Road J; Hoffstein V; Hodder R; Marciniuk D; McCormack D; Fox G; Cox G; Prins HB; Ford G; Bleskie D; Doucette S; Mayers I; Chapman K; Zamel N; FitzGerald M;
    Ann Intern Med; 2007 Apr; 146(8):545-55. PubMed ID: 17310045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parasternal muscle activity decreases in severe COPD with salmeterol-fluticasone propionate.
    Easton PA; Hawes HG; Doig CJ; Johnson MW; Yokoba M; Wilde ER
    Chest; 2010 Mar; 137(3):558-65. PubMed ID: 19820074
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.